Table 1 Clinicopathological correlation of VISTA expression in 183 HCC patients
Feature | Total (N) | VISTA | P | VISTA (tumor cell) | P | VISTA (immune cell) | P | |||
|---|---|---|---|---|---|---|---|---|---|---|
Pos (n, %) | Neg (n, %) | Pos (n, %) | Neg (n, %) | Pos (n, %) | Neg (n, %) | |||||
Age(years) | ||||||||||
> 50 | 108 | 36(33.3%) | 72(66.7%) | 0.173 | 20(18.5%) | 68(81.5%) | 0.351 | 22(20.4%) | 86(79.6%) | 0.138 |
≤ 50 | 75 | 18(24.0%) | 57(76.0%) | 10(13.3%) | 65(86.7%) | 9(12.0%) | 66(88.0%) | |||
Gender | ||||||||||
Male | 157 | 48(30.6%) | 109(69.4%) | 0.438 | 27(17.2%) | 130(82.8%) | 0.470 | 28(17.8%) | 129(82.2%) | 0.428 |
Female | 26 | 6(23.1%) | 20(76.9%) | 3(11.5%) | 23(88.5%) | 3(11.5%) | 23(88.5%) | |||
Tumor size | ||||||||||
≤ 5 cm | 91 | 31(34.1%) | 60(65.9%) | 0.804 | 20(22.0%) | 71(78.0%) | 0.042* | 19(20.9%) | 72(79.1%) | 0.158 |
> 5 cm | 92 | 23(25.0%) | 69(75.0%) | 10(10.9%) | 82(89.1%) | 12(13.0%) | 80(87.0%) | |||
TNM stage | ||||||||||
I | 73 | 25(34.2%) | 48(65.8%) | 0.294 | 13(17.8%) | 60(82.8%) | 0.272 | 17(23.3%) | 56(76.7%) | 0.261 |
II | 60 | 14(23.3%) | 46(76.7%) | 7(11.7%) | 53(88.3%) | 8(13.3%) | 52(86.7%) | |||
III-IV | 42 | 15(35.7%) | 27(64.3%) | 10(23.8%) | 32(76.2%) | 6(14.3%) | 36(85.7%) | |||
Pathological grade | ||||||||||
I-II | 119 | 29(24.4%) | 90(75.6%) | 0.038* | 16(13.4%) | 103(86.6%) | 0.142 | 18(15.1%) | 101(84.9%) | 0.372 |
III-IV | 64 | 25(39.1%) | 39(60.9%) | 14(21.9%) | 50(78.1%) | 13(20.3%) | 51(79.7%) | |||
Liver cirrhosis | ||||||||||
Yes | 69 | 26(22.8%) | 88(77.2%) | 0.011* | 13(11.4%) | 101(88.6%) | 0.019* | 17(14.9%) | 97(85.1%) | 0.347 |
No | 114 | 28(40.6%) | 41(59.4%) | 17(24.6%) | 52(75.4%) | 14(20.3%) | 55(79.7%) | |||
CD8+TILs | ||||||||||
Yes | 61 | 31(50.8%) | 30(49.2%) | 0.000* | 19(31.1%) | 42(68.9%) | 0.000* | 18(29.5%) | 43(70.5%) | 0.001* |
No | 122 | 23(18.9%) | 99(81.1%) | 11(9.0%) | 111(91.0%) | 13(10.7%) | 109(89.3%) | |||